AGENUS INC Business Acquisition, Pro Forma Net Income (Loss)
AGENUS INC (AGEN) reported Business Acquisition, Pro Forma Net Income (Loss) of -$43.28 million for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2016-03-15
- AGENUS INC business acquisition, pro forma net income (loss) for the quarter ending 2014-12-31 was -$26.08M.
- AGENUS INC business acquisition, pro forma net income (loss) for the quarter ending 2014-09-30 was -$8.11M.
- AGENUS INC business acquisition, pro forma net income (loss) for the quarter ending 2013-12-31 was -$8.87M.
- AGENUS INC business acquisition, pro forma net income (loss) for the quarter ending 2013-09-30 was -$8.67M.
- AGENUS INC business acquisition, pro forma net income (loss) for fiscal 2014 was -$43.28M.
- AGENUS INC business acquisition, pro forma net income (loss) for fiscal 2013 was -$39.06M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2014-12-31 | -$26.08M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$34.19M derived: sum of 2 quarters · filed 2016-03-15 | -$43.28M 10-K · filed 2016-03-15 | |
| 2014-09-30 | -$8.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | -$17.20M 10-Q · filed 2014-10-31 | ||
| 2014-06-30 | -$9.09M 10-Q · filed 2014-08-01 | |||
| 2013-12-31 | -$8.87M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$17.54M derived: sum of 2 quarters · filed 2016-03-15 | -$39.06M 10-K · filed 2016-03-15 | |
| 2013-09-30 | -$8.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | -$30.19M 10-Q · filed 2014-10-31 | ||
| 2013-06-30 | -$21.53M 10-Q · filed 2014-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |